Compare VYGR & MCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYGR | MCR |
|---|---|---|
| Founded | 2013 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.0M | 254.3M |
| IPO Year | 2015 | N/A |
| Metric | VYGR | MCR |
|---|---|---|
| Price | $3.76 | $6.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | ★ 837.1K | 92.4K |
| Earning Date | 03-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | ★ $10,135,000.00 | N/A |
| Revenue This Year | $54.19 | N/A |
| Revenue Next Year | $20.22 | N/A |
| P/E Ratio | ★ N/A | $15.92 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.65 | $5.57 |
| 52 Week High | $5.55 | $6.57 |
| Indicator | VYGR | MCR |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 25.86 |
| Support Level | $3.60 | $6.00 |
| Resistance Level | $4.43 | $6.36 |
| Average True Range (ATR) | 0.33 | 0.06 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 4.37 | 16.67 |
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.